News & Views

  • Kayentis Collaborates on Clinical Trial Services Projects with Emerging Biopharma Firms in Europe and US

Kayentis Collaborates on Clinical Trial Services Projects with Emerging Biopharma Firms in Europe and US

Apr 24 2020 Read 583 Times

Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) solutions for clinical trials, has announced it is forging ahead on five new eCOA service projects with Emerging BioPharma (EBP) companies. EBP is a segment of companies driving a large portion of innovation and development in the life sciences and defined as having less than $200 million in estimated annual spending on R&D. The projects Kayentis is collaborating on involve phase 2 and 3 clinical studies in therapeutic areas addressing unmet needs in oncology, inflammation and immune disorders, women’s health and rare diseases.

In response to COVID-19, Kayentis has implemented a dedicated contingency plan for sites and patients, protocols and additional support to enable these EBPs, as well as its other clients, to keep trials running.

Kayentis won the EBP contracts in a competitive bid among global eCOA vendors. Due to confidentiality, the names of the five EBP clients were not disclosed.

“EBPs are significantly influencing the clinical research landscape; they contribute to a large proportion of biomedical innovation,” said Guillaume Juge, CEO at Kayentis. “In recent times, we have seen an uptick in eCOA contracts stemming from the growth in the number of clinical trials being conducted by EBPs. Kayentis is committed to supporting our EBPs to help mitigate the negative consequences of the current health crisis.”

“As EBPs are active in only a limited number of project developments, with limited resources, the stakes for success are extremely high,” explained Estelle Haenel, Medical Director at Kayentis. “Kayentis’ approach to collaboration is to fill infrastructure and resource gaps. Therefore, we are very highly involved in the preliminary consultation and in issuing advice; even more so now, due to the COVID-19 pandemic. The EBPs with whom we are currently engaged solicit our expertise in eCOA and require that we guide them on COVID-19 public notices, as well as support the primary endpoint of their protocols that are critical to their businesses.”

More information online

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

LabAsia Buyers Guide 2020

October 2020

In This Edition Articles - Ambient Ionisation MS and GC-MS Analysis and Identification of Aroma Compounds in Agave Based Alcoholic Beverages - How a Chromatographic Method is More Than a Sep...

View all digital editions


West Africa Water Expo

Oct 06 2020 Lagos, Nigeria


Oct 06 2020 Digital Forum


Oct 07 2020 Lyon, France


Oct 07 2020 Lausanne, Switzerland

View all events